Quick Answer
| What the 503A Bulks List is | What it is not |
|---|---|
| An FDA list of bulk drug substances pharmacies can legally use for traditional compounding | Not a list of FDA-approved drugs |
| One of three legal pathways for compounding a substance under Section 503A | Not the only pathway; a USP-NF monograph or use in an approved drug also qualify |
| Something added only through nomination, expert review, and formal rulemaking | Not something a single advisory committee vote can add on its own |
Section 503A and the Bulks List, Explained
Section 503A of the Federal Food, Drug, and Cosmetic Act (FDCA) governs traditional pharmacy compounding: a licensed pharmacist or physician preparing a specific medication for an individual patient's specific prescription need, rather than manufacturing a drug for general sale. It's a narrower, more tightly regulated activity than commercial drug manufacturing, and it exists to cover cases where a patient needs a formulation, strength, or combination that isn't commercially available.
Not every ingredient can be used this way, though. For a bulk drug substance to legally be used in 503A compounding, it generally has to meet one of three conditions: it appears on the FDA's Section 503A Bulk Drug Substances List, it has an official monograph in the United States Pharmacopeia-National Formulary (USP-NF), or it's a component of an FDA-approved drug. If a substance doesn't meet any of those three conditions, a 503A pharmacy generally can't use it, regardless of demand or perceived safety.
How a Substance Gets Added to the List
Getting a bulk drug substance onto the 503A Bulks List is a multi-step regulatory process, not a decision the FDA makes on its own initiative or overnight.
- Nomination. Any interested party, which can include a compounding pharmacy, a trade group, a manufacturer, or another stakeholder, can formally nominate a substance for the list.
- FDA evaluation. The FDA reviews the nomination and the supporting evidence submitted with it.
- PCAC referral. FDA often refers the nomination to its Pharmacy Compounding Advisory Committee (PCAC), a panel of outside experts, for review and a recommendation vote.
- Committee vote. PCAC votes on whether to recommend the substance. This vote is nonbinding; the FDA isn't required to follow it.
- FDA decision. If the FDA decides to move forward, it has to go through formal notice-and-comment rulemaking rather than simply adding the substance administratively.
- Rulemaking. That process includes publishing a proposed rule, accepting public comments, and eventually issuing a final rule before the substance is actually added to the list.
The July 2026 PCAC Vote on Seven Peptides
This process isn't just theoretical. On July 23 and 24, 2026, PCAC reviewed seven peptides that had been nominated for the 503A Bulks List. BPC-157, KPV, TB-500, and MOTS-c were reviewed on the first day, and Emideltide, the nomination name used for DSIP, along with Semax and Epitalon, were reviewed on the second.
| Compound | Day Reviewed | PCAC Recommendation |
|---|---|---|
| BPC-157 | Day 1 (Jul 23) | Recommended |
| KPV | Day 1 (Jul 23) | Recommended |
| TB-500 | Day 1 (Jul 23) | Recommended |
| MOTS-c | Day 1 (Jul 23) | Recommended |
| Emideltide (DSIP) | Day 2 (Jul 24) | Not recommended |
| Semax | Day 2 (Jul 24) | Recommended |
| Epitalon | Day 2 (Jul 24) | Recommended |
The committee voted to recommend six of the seven peptides, with only Emideltide (DSIP) voted down, and the votes were reported as narrow margins rather than a clear consensus. As of this writing, the FDA has not acted on that recommendation. None of these seven peptides are on the 503A Bulks List, and the recommendation itself does not make compounding any of them legal yet. For the full story behind that vote, see What Changed With BPC-157, TB-500 and MOTS-c in 2026?, and for the current live status of these and other peptides, see the FDA Peptide Status Tracker.
What This Actually Means (and Doesn't)
It's worth being precise about what a spot on the 503A Bulks List actually grants, because it's easy to overstate. Being on the list doesn't mean a substance is FDA-approved as a drug. It hasn't gone through the clinical trial process the FDA uses to evaluate a new medication's safety and effectiveness. It also doesn't mean the substance becomes available over the counter or through general retail; the 503A framework is built entirely around individual prescriptions.
What it does mean, practically, is narrower: a licensed compounding pharmacy could legally prepare the substance for a specific patient who has a valid prescription, under that pharmacy's own quality control, licensing, and record-keeping obligations. It's a pathway to legal compounding, not a stamp of general approval or availability.
Related Reading
For what a compounded peptide actually is and how it differs from a manufactured research chemical, see What Is a Compounded Peptide?. For the full context behind the July 2026 vote on BPC-157, TB-500, and MOTS-c, see What Changed With BPC-157, TB-500 and MOTS-c in 2026?. For the current status of these and other peptides, see the FDA Peptide Status Tracker. For the broader legal picture around buying and using research peptides, see Are Peptides Legal in the United States? 2026 Guide.
Curious how compounds like these fit into a broader protocol? Try BioStackIQ's Rate My Stack tool, or build your own with the Peptide Protocol Builder.